|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAPK1 |
Gene summary for MAPK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAPK1 | Gene ID | 5594 |
| Gene name | mitogen-activated protein kinase 1 | |
| Gene Alias | ERK | |
| Cytomap | 22q11.22 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P28482 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5594 | MAPK1 | LZE4T | Human | Esophagus | ESCC | 1.53e-08 | -1.67e-02 | 0.0811 |
| 5594 | MAPK1 | LZE7T | Human | Esophagus | ESCC | 2.01e-04 | 1.25e-01 | 0.0667 |
| 5594 | MAPK1 | LZE8T | Human | Esophagus | ESCC | 7.17e-05 | -5.36e-02 | 0.067 |
| 5594 | MAPK1 | LZE24T | Human | Esophagus | ESCC | 3.35e-12 | 2.52e-01 | 0.0596 |
| 5594 | MAPK1 | LZE21T | Human | Esophagus | ESCC | 4.39e-06 | 1.56e-01 | 0.0655 |
| 5594 | MAPK1 | P1T-E | Human | Esophagus | ESCC | 3.69e-07 | 1.56e-01 | 0.0875 |
| 5594 | MAPK1 | P2T-E | Human | Esophagus | ESCC | 3.35e-28 | 3.53e-01 | 0.1177 |
| 5594 | MAPK1 | P4T-E | Human | Esophagus | ESCC | 3.45e-33 | 7.06e-01 | 0.1323 |
| 5594 | MAPK1 | P5T-E | Human | Esophagus | ESCC | 3.03e-12 | 1.44e-01 | 0.1327 |
| 5594 | MAPK1 | P8T-E | Human | Esophagus | ESCC | 1.10e-20 | 3.12e-01 | 0.0889 |
| 5594 | MAPK1 | P9T-E | Human | Esophagus | ESCC | 3.75e-14 | 2.21e-01 | 0.1131 |
| 5594 | MAPK1 | P10T-E | Human | Esophagus | ESCC | 6.05e-27 | 4.18e-01 | 0.116 |
| 5594 | MAPK1 | P11T-E | Human | Esophagus | ESCC | 4.98e-20 | 4.32e-01 | 0.1426 |
| 5594 | MAPK1 | P12T-E | Human | Esophagus | ESCC | 1.14e-20 | 4.10e-01 | 0.1122 |
| 5594 | MAPK1 | P15T-E | Human | Esophagus | ESCC | 4.67e-15 | 2.76e-01 | 0.1149 |
| 5594 | MAPK1 | P16T-E | Human | Esophagus | ESCC | 4.99e-17 | 2.27e-01 | 0.1153 |
| 5594 | MAPK1 | P17T-E | Human | Esophagus | ESCC | 3.77e-11 | 3.38e-01 | 0.1278 |
| 5594 | MAPK1 | P19T-E | Human | Esophagus | ESCC | 1.24e-10 | 3.63e-01 | 0.1662 |
| 5594 | MAPK1 | P20T-E | Human | Esophagus | ESCC | 2.18e-18 | 6.41e-02 | 0.1124 |
| 5594 | MAPK1 | P21T-E | Human | Esophagus | ESCC | 5.32e-17 | 1.57e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
| GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
| GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
| GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421818 | Prostate | BPH | Cellular senescence | 60/1718 | 156/8465 | 1.07e-07 | 1.18e-06 | 7.32e-07 | 60 |
| hsa0481020 | Prostate | BPH | Regulation of actin cytoskeleton | 80/1718 | 229/8465 | 1.23e-07 | 1.31e-06 | 8.10e-07 | 80 |
| hsa0520520 | Prostate | BPH | Proteoglycans in cancer | 72/1718 | 205/8465 | 4.16e-07 | 4.10e-06 | 2.54e-06 | 72 |
| hsa0516727 | Prostate | BPH | Kaposi sarcoma-associated herpesvirus infection | 69/1718 | 194/8465 | 4.22e-07 | 4.10e-06 | 2.54e-06 | 69 |
| hsa052037 | Prostate | BPH | Viral carcinogenesis | 69/1718 | 204/8465 | 3.40e-06 | 2.87e-05 | 1.78e-05 | 69 |
| hsa0521016 | Prostate | BPH | Colorectal cancer | 36/1718 | 86/8465 | 3.94e-06 | 3.25e-05 | 2.01e-05 | 36 |
| hsa0516326 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
| hsa0513518 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
| hsa041515 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
| hsa052129 | Prostate | BPH | Pancreatic cancer | 31/1718 | 76/8465 | 3.36e-05 | 2.47e-04 | 1.53e-04 | 31 |
| hsa0472325 | Prostate | BPH | Retrograde endocannabinoid signaling | 51/1718 | 148/8465 | 3.59e-05 | 2.57e-04 | 1.59e-04 | 51 |
| hsa0491527 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
| hsa0406625 | Prostate | BPH | HIF-1 signaling pathway | 40/1718 | 109/8465 | 4.97e-05 | 3.35e-04 | 2.07e-04 | 40 |
| hsa046688 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
| hsa0522016 | Prostate | BPH | Chronic myeloid leukemia | 30/1718 | 76/8465 | 9.26e-05 | 5.77e-04 | 3.57e-04 | 30 |
| hsa0514518 | Prostate | BPH | Toxoplasmosis | 40/1718 | 112/8465 | 1.00e-04 | 6.00e-04 | 3.71e-04 | 40 |
| hsa0421016 | Prostate | BPH | Apoptosis | 46/1718 | 136/8465 | 1.41e-04 | 8.31e-04 | 5.14e-04 | 46 |
| hsa0541728 | Prostate | BPH | Lipid and atherosclerosis | 66/1718 | 215/8465 | 1.68e-04 | 9.56e-04 | 5.92e-04 | 66 |
| hsa049338 | Prostate | BPH | AGE-RAGE signaling pathway in diabetic complications | 36/1718 | 100/8465 | 1.82e-04 | 1.02e-03 | 6.30e-04 | 36 |
| hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| MAPK1 | CD8TEXINT | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.57e-01 |  |
| MAPK1 | CD8TEREX | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.43e-01 | |
| MAPK1 | MAIT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.38e-01 |  |
| MAPK1 | CD8TEREX | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.84e-01 | |
| MAPK1 | CD8TEXINT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.00e-01 | |
| MAPK1 | CD8TEREX | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 6.38e-02 |  |
| MAPK1 | TREG | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 1.20e-01 | |
| MAPK1 | TH17 | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 8.39e-02 |  |
| MAPK1 | CD8TEREX | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 2.37e-01 | |
| MAPK1 | MAIT | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 1.13e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAPK1 | SNV | Missense_Mutation | c.241G>A | p.Glu81Lys | p.E81K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
| MAPK1 | SNV | Missense_Mutation | rs747124623 | c.994G>A | p.Asp332Asn | p.D332N | P28482 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| MAPK1 | insertion | Frame_Shift_Ins | novel | c.1024_1025insTTGTGAGCCAAGGTAGAAGCAGTTGCTGGGGAGATGC | p.Lys342IlefsTer20 | p.K342Ifs*20 | P28482 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MAPK1 | SNV | Missense_Mutation | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MAPK1 | SNV | Missense_Mutation | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| MAPK1 | SNV | Missense_Mutation | c.961G>A | p.Asp321Asn | p.D321N | P28482 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MAPK1 | SNV | Missense_Mutation | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MAPK1 | SNV | Missense_Mutation | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAPK1 | SNV | Missense_Mutation | c.404G>A | p.Arg135Lys | p.R135K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAPK1 | SNV | Missense_Mutation | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | PROGESTERONE | PROGESTERONE | ||
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | SPINASAPONIN A METHYL ESTER | SPINASAPONIN A METHYL ESTER | 20951582 | |
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | ||
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | TREQUINSIN HYDROCHLORIDE | TREQUINSIN HYDROCHLORIDE | ||
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 | |
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | PHENETHYLISOTHIOCYANATE | PHENETHYLISOTHIOCYANATE | 22607231 | |
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | GENTIAN VIOLET | GENTIAN VIOLET | ||
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | MITOXANTRONE DIHYDROCHLORIDE | MITOXANTRONE HYDROCHLORIDE | ||
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | ||
| 5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | ZM-449829 | CHEMBL154580 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |